JNCE - Jounce Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
167,972
65,201
71,644
37,197
0
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
67,169
70,052
67,798
34,904
22,130
Selling General and Administrative
27,599
26,443
23,061
16,759
8,266
Total Operating Expenses
94,768
96,495
90,859
51,663
30,396
Operating Income or Loss
73,204
-31,294
-19,215
-14,466
-30,396
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
4,328
3,961
2,808
763
5
Income Before Tax
77,532
-27,333
-16,407
-13,703
-28,532
Income Tax Expense
82
46
36
-
-
Income from Continuing Operations
77,450
-27,379
-16,443
-13,703
-28,532
Net Income
77,450
-27,379
-16,443
-13,703
-30,611
Net Income available to common shareholders
77,450
-27,379
-17,237
-23,138
-37,503
Reported EPS
Basic
-
-0.84
-0.57
-0.77
-1.64
Diluted
-
-0.84
-0.57
-0.77
-1.64
Weighted average shares outstanding
Basic
-
32,567
30,055
30,162
18,522
Diluted
-
32,567
30,055
30,162
18,522
EBITDA
-
-27,463
-14,793
-12,522
-28,926